PT-502 uses the dopamine system in order to treat depression, a
mechanism of action which is different to traditional serotonin and
norepinephrine reuptake inhibitors such as Prozac.
The compound is one of a series of Ritalin-like compounds developed by
Dr Mark Froimowitz, research professor of chemistry at the Boston
College, which the company licensed in October 2005.
Ritalin is a well-known drug used for the treatment of attention
deficit hyperactivity disorder (ADHD). These compounds have the
potential to be enhanced pharmaceuticals for the clinical treatment of
depression, drug addiction and ADHD.
Dr Froimowitz noted that 30% or more of the patients treated with
available anti-depressants either do not respond to treatment or have
adverse side effects.
"PT-502 is our new compound designed to selectively block the reuptake
of dopamine with a slow onset, and a longer duration of action. This
pharmacokinetic profile indicates that PT-502 should have little or no
abuse potential. This offers a new model for the treatment of
depression that affects nearly 20 million people a year in the US
alone," said Dr Froimowitz.
Labels: No Prescription, Online Pharmacy, Prescription Drugs
# posted by Network @ 8:34 AM
